Pralatrexate-Induced Toxic Epidermal Necrolysis

Amaç & Hipotez:SCORTEN is an seven parametered index which is developed for TEN in order to predict the severity of disease and risk of mortality.

📊

Temel Bulgular & Veri:One point is given for each of the following factors: 1) age > 40 years 2) malignancy 3) serum bicarbonate 120/minute 5) serum glucose > 252 mg/dl 6) epidermal detachment > 10% of body surface area 7) serum blood urea nitrogen >28 mg/ dl.4 The mortality rate of TEN is approximately 25% to 30%.

💡

Sonuç & Katkı:Antifolate drugs cause, focal or widespread epi- dermal necrosis.the skin reaction is high probably

🔬Tür:Araştırma Makalesi

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Alan Parametreleri

Abstract

SCORTEN is an seven parametered index which is developed for TEN in order to predict the severity of disease and risk of mortality. One point is given for each of the following factors: 1) age > 40 years 2) malignancy 3) serum bicarbonate 120/minute 5) serum glucose > 252 mg/dl 6) epidermal detachment > 10% of body surface area 7) serum blood urea nitrogen >28 mg/ dl.4 The mortality rate of TEN is approximately 25% to 30%. The mortality risk increases accord- ing to SCORTEN score. Mortality rate is 90% for those with ≥ 5 points in SCORTEN parametres.5 It has recommended that SCORTEN score has been evaluated on day 1and day 3 in hospitaliza- tion for TEN diagnosed patient.6 In our case , SCORTEN score for day 1 was graded four and it was graded six for day 3. In addition- ally, we observed a serious grade 4 myelosupres- sion due to pralatrexate. Antifolate drugs cause, focal or widespread epi- dermal necrosis.the skin reaction is high probably

🔖

Bu Makaleye Atıf Yap

DEMIRSOY, E. T., TARKUN, P., MEHTAP, Ö., ATESOGLU, E. B., GEDUK, A., DEMIRSOY², E. O., HACIHANEFİOĞLU, A. (2017). Pralatrexate-Induced Toxic Epidermal Necrolysis. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 27 - Sayı: 4, 53–55. https://ajindex.com/articles/323139

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol 69: 185-186, 2013
StatBite. FDA oncology drug product approvals in 2009. J Natl Cancer Inst 102: 219, 2010
O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29: 1182-1189, 2011
Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115: 149-153, 2000
Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol 69: 187.e1-16; quiz 203-204, 2013
Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 126: 272-276, 2006
Pierard-Franchimont C, Lesuisse M, Humbert P, et al. Toxic epidermal necrolysis and antifolate drugs in cancer chemotherapy. Curr Drug Saf 7: 357-360, 2012
Primka EJ, Camisa C. Methotrexate-induced toxic epidermal necrolysis in a patient with psoriasis. J Am Acad Dermatol 36: 815-818, 1997
Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119: 4115- 4122, 2012
Koch E, Story SK, Geskin LJ. Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy. Leuk Lymphoma 54: 2448-2451, 2013.